Detalhe da pesquisa
1.
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
J Am Acad Dermatol
; 84(2): 398-407, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961255
2.
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
J Drugs Dermatol
; 19(8): 703-708, 2020 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845115
3.
IL-17 inhibitors for psoriasis.
Semin Cutan Med Surg
; 37(3): 148-157, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30215631
4.
The Evolving Landscape of Psoriasis Treatment.
Semin Cutan Med Surg
; 37(2S): S39-S43, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29614136
5.
Treating to Target-A Realistic Goal in Psoriasis?
Semin Cutan Med Surg
; 37(2S): S44-S47, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29614137
6.
Common and Not-So-Common Comorbidities of Psoriasis.
Semin Cutan Med Surg
; 37(2S): S48-S51, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29614138
7.
Practical Strategies for Optimizing Management of Psoriasis.
Semin Cutan Med Surg
; 37(2S): S52-S55, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29614139
8.
Spectrum of orocutaneous disease associations: Immune-mediated conditions.
J Am Acad Dermatol
; 77(5): 795-806, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29029901
9.
Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditions.
J Am Acad Dermatol
; 77(5): 809-830, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29029902
10.
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.
J Am Acad Dermatol
; 76(2): 290-298, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908543
11.
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
J Drugs Dermatol
; 15(5): 568-80, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27168266
12.
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease.
J Am Acad Dermatol
; 70(5): 795.e1-25, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742848
13.
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease.
J Am Acad Dermatol
; 70(5): 821.e1-19, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742849
14.
Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
J Drugs Dermatol
; 11(11): 1348-54, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23135087
15.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Dermatol Ther (Heidelb)
; 12(2): 495-510, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025062
16.
Erythema Ab Igne and Malignant Transformation to Squamous Cell Carcinoma.
Cutis
; 107(1): 51-53, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651859
17.
Reply to: "Review of drug-related causes of oculocutaneous disease".
J Am Acad Dermatol
; 72(2): 362-3, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25592349
18.
Awareness and engagement in political advocacy among dermatology residents: a needs assessment.
J Am Acad Dermatol
; 72(4): 730-2, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25773414
19.
Histiocytoid Sweet syndrome successfully treated with etanercept.
Proc (Bayl Univ Med Cent)
; 31(3): 347-349, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29904308
20.
Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas.
Expert Opin Pharmacother
; 19(6): 561-575, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29565192